Dialyzable Leukocyte Extract (Transferon™) Administration in Sepsis: Experience from a Single Referral Pediatric Intensive Care Unit

Maria Isabel Castrejón Vázquez, Aldo Arturo Reséndiz-Albor, Mario A. Ynga-Durand, Ivonne Mac Iel Arciniega Martínez, Vanessa Ivonne Orellana-Villazon, Carlos Alberto García López, Maria Laura Laue Noguera, Maria Eugenia Vargas Camaño

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Immunomodulatory agents have been proposed as therapeutic candidates to improve outcomes in sepsis. Transferon™, a dialyzable leukocyte extract (DLE), has been supported in Mexico as an immunomodulatory adjuvant in anti-infectious therapy. Here we present a retrospective study describing the experience of a referral pediatric intensive care unit (PICU) with Transferon™ in sepsis. We studied clinical and laboratory data from 123 patients with sepsis (15 in the DLE group and 108 in the control group) that were admitted to PICU during the period between January 2010 and December 2016. Transferon™ DLE use was associated with lower C reactive protein (CRP), increase in total lymphocyte counts (TLC), and decrease in total neutrophil count (TNC) 72 hours after Transferon™ DLE administration. The control group did not present any significant difference in CRP values and had lower TLC after 72 hours of admission. There was no difference in PICU length of stay between control and Transferon™ DLE group. Transferon™ DLE administration was associated with a higher survival rate at the end of PICU stay. This study shows a possible immunomodulatory effect of Transferon™ on pediatric sepsis patients.

Original languageEnglish
Article number8980506
JournalBioMed Research International
Volume2019
DOIs
StatePublished - 1 Jan 2019

Fingerprint

Transfer Factor
Intensive care units
Pediatric Intensive Care Units
Pediatrics
Sepsis
Referral and Consultation
Lymphocytes
Lymphocyte Count
C-Reactive Protein
Control Groups
Mexico
Length of Stay
Neutrophils
Survival Rate
Retrospective Studies
Therapeutics

Cite this

Castrejón Vázquez, Maria Isabel ; Reséndiz-Albor, Aldo Arturo ; Ynga-Durand, Mario A. ; Arciniega Martínez, Ivonne Mac Iel ; Orellana-Villazon, Vanessa Ivonne ; García López, Carlos Alberto ; Laue Noguera, Maria Laura ; Vargas Camaño, Maria Eugenia. / Dialyzable Leukocyte Extract (Transferon™) Administration in Sepsis: Experience from a Single Referral Pediatric Intensive Care Unit. In: BioMed Research International. 2019 ; Vol. 2019.
@article{a2d4ed607dd148e0b40a580ebbd00918,
title = "Dialyzable Leukocyte Extract (Transferon™) Administration in Sepsis: Experience from a Single Referral Pediatric Intensive Care Unit",
abstract = "Immunomodulatory agents have been proposed as therapeutic candidates to improve outcomes in sepsis. Transferon™, a dialyzable leukocyte extract (DLE), has been supported in Mexico as an immunomodulatory adjuvant in anti-infectious therapy. Here we present a retrospective study describing the experience of a referral pediatric intensive care unit (PICU) with Transferon™ in sepsis. We studied clinical and laboratory data from 123 patients with sepsis (15 in the DLE group and 108 in the control group) that were admitted to PICU during the period between January 2010 and December 2016. Transferon™ DLE use was associated with lower C reactive protein (CRP), increase in total lymphocyte counts (TLC), and decrease in total neutrophil count (TNC) 72 hours after Transferon™ DLE administration. The control group did not present any significant difference in CRP values and had lower TLC after 72 hours of admission. There was no difference in PICU length of stay between control and Transferon™ DLE group. Transferon™ DLE administration was associated with a higher survival rate at the end of PICU stay. This study shows a possible immunomodulatory effect of Transferon™ on pediatric sepsis patients.",
author = "{Castrej{\'o}n V{\'a}zquez}, {Maria Isabel} and Res{\'e}ndiz-Albor, {Aldo Arturo} and Ynga-Durand, {Mario A.} and {Arciniega Mart{\'i}nez}, {Ivonne Mac Iel} and Orellana-Villazon, {Vanessa Ivonne} and {Garc{\'i}a L{\'o}pez}, {Carlos Alberto} and {Laue Noguera}, {Maria Laura} and {Vargas Cama{\~n}o}, {Maria Eugenia}",
year = "2019",
month = "1",
day = "1",
doi = "10.1155/2019/8980506",
language = "Ingl{\'e}s",
volume = "2019",
journal = "Default journal",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

Dialyzable Leukocyte Extract (Transferon™) Administration in Sepsis: Experience from a Single Referral Pediatric Intensive Care Unit. / Castrejón Vázquez, Maria Isabel; Reséndiz-Albor, Aldo Arturo; Ynga-Durand, Mario A.; Arciniega Martínez, Ivonne Mac Iel; Orellana-Villazon, Vanessa Ivonne; García López, Carlos Alberto; Laue Noguera, Maria Laura; Vargas Camaño, Maria Eugenia.

In: BioMed Research International, Vol. 2019, 8980506, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dialyzable Leukocyte Extract (Transferon™) Administration in Sepsis: Experience from a Single Referral Pediatric Intensive Care Unit

AU - Castrejón Vázquez, Maria Isabel

AU - Reséndiz-Albor, Aldo Arturo

AU - Ynga-Durand, Mario A.

AU - Arciniega Martínez, Ivonne Mac Iel

AU - Orellana-Villazon, Vanessa Ivonne

AU - García López, Carlos Alberto

AU - Laue Noguera, Maria Laura

AU - Vargas Camaño, Maria Eugenia

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Immunomodulatory agents have been proposed as therapeutic candidates to improve outcomes in sepsis. Transferon™, a dialyzable leukocyte extract (DLE), has been supported in Mexico as an immunomodulatory adjuvant in anti-infectious therapy. Here we present a retrospective study describing the experience of a referral pediatric intensive care unit (PICU) with Transferon™ in sepsis. We studied clinical and laboratory data from 123 patients with sepsis (15 in the DLE group and 108 in the control group) that were admitted to PICU during the period between January 2010 and December 2016. Transferon™ DLE use was associated with lower C reactive protein (CRP), increase in total lymphocyte counts (TLC), and decrease in total neutrophil count (TNC) 72 hours after Transferon™ DLE administration. The control group did not present any significant difference in CRP values and had lower TLC after 72 hours of admission. There was no difference in PICU length of stay between control and Transferon™ DLE group. Transferon™ DLE administration was associated with a higher survival rate at the end of PICU stay. This study shows a possible immunomodulatory effect of Transferon™ on pediatric sepsis patients.

AB - Immunomodulatory agents have been proposed as therapeutic candidates to improve outcomes in sepsis. Transferon™, a dialyzable leukocyte extract (DLE), has been supported in Mexico as an immunomodulatory adjuvant in anti-infectious therapy. Here we present a retrospective study describing the experience of a referral pediatric intensive care unit (PICU) with Transferon™ in sepsis. We studied clinical and laboratory data from 123 patients with sepsis (15 in the DLE group and 108 in the control group) that were admitted to PICU during the period between January 2010 and December 2016. Transferon™ DLE use was associated with lower C reactive protein (CRP), increase in total lymphocyte counts (TLC), and decrease in total neutrophil count (TNC) 72 hours after Transferon™ DLE administration. The control group did not present any significant difference in CRP values and had lower TLC after 72 hours of admission. There was no difference in PICU length of stay between control and Transferon™ DLE group. Transferon™ DLE administration was associated with a higher survival rate at the end of PICU stay. This study shows a possible immunomodulatory effect of Transferon™ on pediatric sepsis patients.

UR - http://www.scopus.com/inward/record.url?scp=85068969024&partnerID=8YFLogxK

U2 - 10.1155/2019/8980506

DO - 10.1155/2019/8980506

M3 - Artículo

C2 - 31341910

AN - SCOPUS:85068969024

VL - 2019

JO - Default journal

JF - Default journal

SN - 2314-6133

M1 - 8980506

ER -